<DOC>
	<DOCNO>NCT00355121</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety concomitant administration Menactra® vaccine DAPTACEL® vaccine . The main objective : Immunogenicity : To evaluate antibody response vaccine Menactra vaccine give concomitantly DAPTACEL® compare either vaccine give alone . Safety : To evaluate rate local systemic reaction DAPTACEL® Menactra vaccine administer concomitantly compare vaccine give alone .</brief_summary>
	<brief_title>Study Menactra® Children Aged 4 6 Years When Administered Concomitantly With Fifth Dose DAPTACEL®</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy , determine medical history physical examination . Aged 4 &lt; 7 year time study vaccination Day 0 . Informed consent form approve Institutional Review Board ( IRB ) signed/dated parent legal guardian . Previous documented vaccination history 4th dose diphtheria , tetanus acellular pertussis ( DTaP ) series . Serious chronic disease ( e.g . cardiac , renal , neurologic , metabolic , rheumatologic , psychiatric , hematologic ) Known suspect impairment immunologic function Acute medical illness without fever within last 72 hour temperature ≥ 100.4°F ( ≥ 38°C ) time enrollment History document invasive meningococcal disease previous meningococcal vaccination Received 5th dose vaccination tetanus , diphtheria pertussis vaccine , 4th dose IPV prior study . Received either immune globulin blood product within last 3 month ; receive injected oral corticosteroid , immunomodulator therapy , within 6 week study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day individual ( e.g. , asthmatic ) short schedule oral steroid last 3 4 day may include trial long receive one course within last 2 week prior enrollment . Received oral inject antibiotic therapy within 72 hour prior blood draw . Suspected known hypersensitivity study vaccine component , history serious lifethreatening reaction trial vaccine vaccine contain substance . Thrombocytopenia bleed disorder contraindicate IM vaccination . Unavailable entire study period , unable attend schedule visit comply study procedure . Enrolled another clinical trial . Diagnosed condition , , opinion physician investigator , would pose health risk subject interfere evaluation vaccine . Received vaccine 30 day prior first study vaccination schedule receive vaccination course study . Personal family history GuillainBarré Syndrome ( GBS ) .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Meningococcal meningitis</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>Neisseria meningitidis</keyword>
</DOC>